Cargando…

Faecal Microbiota in Patients with Neurogenic Bowel Dysfunction and Spinal Cord Injury or Multiple Sclerosis—A Systematic Review

Background: Neurogenic bowel dysfunction (NBD) frequently occurs in patients with spinal cord injury (SCI) and multiple sclerosis (MS) with comparable symptoms and is often difficult to treat. It has been suggested the gut microbiota might influence the course of NBD. We systematically reviewed the...

Descripción completa

Detalles Bibliográficos
Autores principales: Faber, Willemijn, Stolwijk-Swuste, Janneke, van Ginkel, Florian, Nachtegaal, Janneke, Zoetendal, Erwin, Winkels, Renate, Witteman, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068808/
https://www.ncbi.nlm.nih.gov/pubmed/33918927
http://dx.doi.org/10.3390/jcm10081598
_version_ 1783683089454596096
author Faber, Willemijn
Stolwijk-Swuste, Janneke
van Ginkel, Florian
Nachtegaal, Janneke
Zoetendal, Erwin
Winkels, Renate
Witteman, Ben
author_facet Faber, Willemijn
Stolwijk-Swuste, Janneke
van Ginkel, Florian
Nachtegaal, Janneke
Zoetendal, Erwin
Winkels, Renate
Witteman, Ben
author_sort Faber, Willemijn
collection PubMed
description Background: Neurogenic bowel dysfunction (NBD) frequently occurs in patients with spinal cord injury (SCI) and multiple sclerosis (MS) with comparable symptoms and is often difficult to treat. It has been suggested the gut microbiota might influence the course of NBD. We systematically reviewed the literature on the composition of the gut microbiota in SCI and MS, and the possible role of neurogenic bowel function, diet and antibiotic use. Methods: A systematic search was conducted in PubMed and Embase, which retrieved studies on the gut microbiota in SCI and MS. The Newcastle–Ottawa Quality Assessment Scale (NOS) was used to assess methodological quality. Results: We retrieved fourteen papers (four on SCI, ten on MS), describing the results of a total of 479 patients. The number of patients per study varied from 13 to 89 with an average of 34. Thirteen papers were observational studies and one study was an intervention study. The studies were case control studies in which the gut microbiota composition was determined by 16S rRNA gene sequencing. The methodological quality of the studies was mostly rated to be moderate. Results of two studies suggested that alpha diversity in chronic SCI patients is lower compared to healthy controls (HC), whereas results from five studies suggest that the alpha diversity of MS patients is similar compared to healthy subjects. The taxonomic changes in MS and SCI studies are diverse. Most studies did not account for possible confounding by diet, antibiotic use and bowel function. Conclusion: Based on these 14 papers, we cannot draw strong conclusions on the composition of the gut microbiota in SCI and MS patients. Putatively, alpha diversity in chronic SCI patients may be lower compared to healthy controls, while in MS patients, alpha diversity may be similar or lower compared to healthy controls. Future studies should provide a more detailed description of clinical characteristics of participants and of diet, antibiotic use and bowel function in order to make valid inferences on changes in gut microbiota and the possible role of diet, antibiotic use and bowel function in those changes.
format Online
Article
Text
id pubmed-8068808
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80688082021-04-26 Faecal Microbiota in Patients with Neurogenic Bowel Dysfunction and Spinal Cord Injury or Multiple Sclerosis—A Systematic Review Faber, Willemijn Stolwijk-Swuste, Janneke van Ginkel, Florian Nachtegaal, Janneke Zoetendal, Erwin Winkels, Renate Witteman, Ben J Clin Med Review Background: Neurogenic bowel dysfunction (NBD) frequently occurs in patients with spinal cord injury (SCI) and multiple sclerosis (MS) with comparable symptoms and is often difficult to treat. It has been suggested the gut microbiota might influence the course of NBD. We systematically reviewed the literature on the composition of the gut microbiota in SCI and MS, and the possible role of neurogenic bowel function, diet and antibiotic use. Methods: A systematic search was conducted in PubMed and Embase, which retrieved studies on the gut microbiota in SCI and MS. The Newcastle–Ottawa Quality Assessment Scale (NOS) was used to assess methodological quality. Results: We retrieved fourteen papers (four on SCI, ten on MS), describing the results of a total of 479 patients. The number of patients per study varied from 13 to 89 with an average of 34. Thirteen papers were observational studies and one study was an intervention study. The studies were case control studies in which the gut microbiota composition was determined by 16S rRNA gene sequencing. The methodological quality of the studies was mostly rated to be moderate. Results of two studies suggested that alpha diversity in chronic SCI patients is lower compared to healthy controls (HC), whereas results from five studies suggest that the alpha diversity of MS patients is similar compared to healthy subjects. The taxonomic changes in MS and SCI studies are diverse. Most studies did not account for possible confounding by diet, antibiotic use and bowel function. Conclusion: Based on these 14 papers, we cannot draw strong conclusions on the composition of the gut microbiota in SCI and MS patients. Putatively, alpha diversity in chronic SCI patients may be lower compared to healthy controls, while in MS patients, alpha diversity may be similar or lower compared to healthy controls. Future studies should provide a more detailed description of clinical characteristics of participants and of diet, antibiotic use and bowel function in order to make valid inferences on changes in gut microbiota and the possible role of diet, antibiotic use and bowel function in those changes. MDPI 2021-04-09 /pmc/articles/PMC8068808/ /pubmed/33918927 http://dx.doi.org/10.3390/jcm10081598 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Faber, Willemijn
Stolwijk-Swuste, Janneke
van Ginkel, Florian
Nachtegaal, Janneke
Zoetendal, Erwin
Winkels, Renate
Witteman, Ben
Faecal Microbiota in Patients with Neurogenic Bowel Dysfunction and Spinal Cord Injury or Multiple Sclerosis—A Systematic Review
title Faecal Microbiota in Patients with Neurogenic Bowel Dysfunction and Spinal Cord Injury or Multiple Sclerosis—A Systematic Review
title_full Faecal Microbiota in Patients with Neurogenic Bowel Dysfunction and Spinal Cord Injury or Multiple Sclerosis—A Systematic Review
title_fullStr Faecal Microbiota in Patients with Neurogenic Bowel Dysfunction and Spinal Cord Injury or Multiple Sclerosis—A Systematic Review
title_full_unstemmed Faecal Microbiota in Patients with Neurogenic Bowel Dysfunction and Spinal Cord Injury or Multiple Sclerosis—A Systematic Review
title_short Faecal Microbiota in Patients with Neurogenic Bowel Dysfunction and Spinal Cord Injury or Multiple Sclerosis—A Systematic Review
title_sort faecal microbiota in patients with neurogenic bowel dysfunction and spinal cord injury or multiple sclerosis—a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068808/
https://www.ncbi.nlm.nih.gov/pubmed/33918927
http://dx.doi.org/10.3390/jcm10081598
work_keys_str_mv AT faberwillemijn faecalmicrobiotainpatientswithneurogenicboweldysfunctionandspinalcordinjuryormultiplesclerosisasystematicreview
AT stolwijkswustejanneke faecalmicrobiotainpatientswithneurogenicboweldysfunctionandspinalcordinjuryormultiplesclerosisasystematicreview
AT vanginkelflorian faecalmicrobiotainpatientswithneurogenicboweldysfunctionandspinalcordinjuryormultiplesclerosisasystematicreview
AT nachtegaaljanneke faecalmicrobiotainpatientswithneurogenicboweldysfunctionandspinalcordinjuryormultiplesclerosisasystematicreview
AT zoetendalerwin faecalmicrobiotainpatientswithneurogenicboweldysfunctionandspinalcordinjuryormultiplesclerosisasystematicreview
AT winkelsrenate faecalmicrobiotainpatientswithneurogenicboweldysfunctionandspinalcordinjuryormultiplesclerosisasystematicreview
AT wittemanben faecalmicrobiotainpatientswithneurogenicboweldysfunctionandspinalcordinjuryormultiplesclerosisasystematicreview